RxDoctor Payments Data

Malik Khan, MD

Hospitalist · Old Bridge, NJNPI 1295905370

Payments from drug & device makers

$526in general payments, 2019–2025

Across 13 payments — averaging $40.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$263
  • Medtronic$146
  • Aimmune Therapeutics, Inc.$35
  • Novartis$19
  • Johnson & Johnson$18
  • Smith+Nephew$17
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$526 in reported general payments places this provider in the 75th percentile of 567 hospitalist providers in New Jersey.

See all hospitalist providers in New Jersey

Medicare billing

Part B allowed, 2024
$208,234
Medicare patients
565
Services billed
1,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$43,332
Darunavir40$12,900
XareltoRivaroxaban40$11,086
FarxigaDapagliflozin Propanediol23$7,135
JanuviaSitagliptin Phosphate29$6,368
EntrestoSacubitril/Valsartan18$4,796
Sevelamer Hcl39$3,409
Vancomycin Hcl19$2,880
Atorvastatin Calcium344$1,535
Ritonavir40$1,508
Midodrine Hcl63$1,394
Duloxetine Hcl85$1,321
Pantoprazole Sodium142$1,174
Methenamine Hippurate38$1,138
Gabapentin192$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$11,08640 claims
AstraZenecaFarxiga$263$7,13523 claims
NovartisEntresto$19$4,79618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 567 hospitalist providers in New Jersey.

Other hospitalist in Old Bridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →